Vectura Group Власний капітал 2024

Що робить Vectura Group?

The Vectura Group PLC is a British company specializing in the development of inhalable medications. The company was founded in 1997 and is headquartered in Chippenham, England. History: Initially, Vectura focused on the development of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). In 2014, the company acquired competitor Skyepharma, expanding its product range to include a wider spectrum of inhalable medications and active ingredients. Business Model: Vectura's business model is based on collaborating with its partners to develop inhalable therapies and active ingredients. The company itself acts as a service provider, offering support to the pharmaceutical industry in the development of new solutions. Vectura has a wide range of technologies and expertise to offer its customers tailored solutions. Divisions: Vectura is divided into four different business units. "Inhaled Therapies" offers solutions for inhaling medications, including inhalers equipped with special propellants to deliver the active ingredients directly to the lungs. The "Royalty-Driven Products" division includes products for which Vectura holds licenses and benefits from the sales of these products. In the "Device Services" division, the company offers development and design services for inhalable therapies. Finally, Vectura also has a research department referred to as "New Product Opportunities," where the company works on the development of new technologies and therapies. Products: Vectura's key products include treatments for asthma and COPD, such as the inhaler Flutiform and the medication Seebri. The company also offers inhalable therapies for other diseases, such as cystic fibrosis and pulmonary hypertension. In addition to medical applications, Vectura also develops more sustainable inhalers and devices that do not rely on chlorofluorocarbons (CFCs) or other environmentally harmful propellants. Conclusion: Vectura has established itself as one of the leading companies in the field of inhalable medications. The company offers tailored solutions for its customers and invests in the development of new technologies to enhance inhalation therapy. Vectura has expanded its portfolio in recent years through the acquisition of Skyepharma and aims to further expand its market position. Vectura Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.